Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | MMP13 | P45452 | 5/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20099655 | 0.85 | GPR119 (0.45) | GPR119USP30MMP13MMP1STS | |
| SCHEMBL20099648 | 0.85 | GPR119 (0.47) | GPR119USP30PRMT5WDR77 | |
| SCHEMBL18183476 | 0.84 | GPR119 (0.47) | GPR119MMP13MMP1STS | |
| SCHEMBL18183707 | 0.80 | MMP13 (0.48) | GPR119MMP13 | |
| SCHEMBL18183590 | 0.79 | GPR119 (0.42) | GPR119USP30NR1H2 | |
| SCHEMBL28184473 | 0.76 | MMP13 (0.47) | GPR119MMP13MMP1STS | |
| SCHEMBL30478340 | 0.75 | GPR119 (0.46) | GPR119MMP13MMP1 | |
| SCHEMBL25874548 | 0.75 | GPR119 (0.46) | GPR119MMP13MMP1 | |
| SCHEMBL20099649 | 0.75 | GPR119 (0.42) | GPR119USP30 | |
| SCHEMBL1328345 | 0.74 | GPR119 (0.53) | GPR119MMP13MMP1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118750-A1 | IMIDAZO ISOINDOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118750-A1 | IMIDAZO ISOINDOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | IDO1, IDO2, TPH1 | GPR119 170/4885USP30 4380/4885MMP13 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.